Theorem Clinical Research, previously Omnicare CR, has been awarded a multi-year contract to conduct Phase III trials for Nordion’s liver cancer therapy TheraSphere.

Theorem will provide clinical trial implementation services, including clinical data management, statistical analysis, monitoring, and administrative expertise to support the studies. The trials are designed to evaluate the safety and effectiveness of TheraSphere, a therapy that consists of millions of small glass beads containing radioactive yttrium-90 (Y-90). The product is injected into the liver through a catheter, allowing the treatment to be delivered directly to the tumor via blood vessels.

“We‘re pleased to have this opportunity to support Nordion on such a groundbreaking therapy,” said Dr. Lee Spurgin, vice president, Clinical Development for Theorem’s Medical Device Business Unit. “We’re a seasoned medical device company with a strong history of recruiting patients into global oncology trials. Because our project teams have both oncology and device experience, we have the right expertise to successfully execute these complex trials in an expeditious timeframe.”